Methods and compositions of improved modified siRNA
Chemically modified small interfering RNAs (siRNAs) that include both phosphorodithioate modifications (PS2-RNA) and 2′-O-methyl modifications (MePS2) provide improved RNA silencing. Specific chemically modified siRNA that show enhanced silencing of RNAs involved in resistance to chemotherapeutic agents are provided.
1. A chemically modified siRNA directed to interference with a RISC Ago2 slicer associated with chemoresistance in ovarian cancer cell lines and tumors, wherein the chemical modifications to the siRNA comprise a combination of 2′-OMe and PS2 modifications on either or both sense and antisense strands of the siRNA that improve serum stability and gene silencing efficacy.
2. A chemically modified siRNA directed to interference with a GRAM Domain Containing 1B (GRAMD1B) associated with chemoresistance, wherein the chemical modifications to the siRNA comprise a combination of 2′-OMe and PS2 modifications on either or both sense and antisense strands of the siRNA that improve serum stability and gene silencing efficacy.
3. A combination therapy for cancer chemotherapy comprising a chemotherapeutic agent and a chemically modified siRNA that interferes with expression of a protein conferring resistance to the chemotherapeutic agent, wherein the chemical modifications to the siRNA comprise a combination of 2′-OMe and PS2 modifications on either or both sense and antisense strands of the siRNA that improve serum stability and gene silencing efficacy of the siRNA.
4. A method of improving serum stability and gene silencing efficacy of the siRNA directed to interference with a RISC Ago2 slicer associated with chemoresistance in ovarian cancer cell lines and tumors comprising introducing a combination of 2′-OMe and PS2 modifications on either or both sense and antisense strands of the siRNA and testing for improved serum stability and gene silencing efficacy of the siRNA.
5. A method of improving serum stability and gene silencing efficacy of the siRNA directed to interference with a GRAM Domain Containing 1B (GRAMD1B) associated with chemoresistance comprising introducing a combination of 2′-OMe and PS2 modifications on either or both sense and antisense strands of the siRNA and testing for improved serum stability and gene silencing efficacy of the siRNA.
6. The chemically modified siRNA of claim 1 , wherein both sense and antisense-strands of the siRNA contain dTdT on their 3′ terminus.
7. The chemically modified siRNA of claim 2 , wherein both sense and antisense-strands of the siRNA contain dTdT on their 3′ terminus.
8. The chemically modified siRNA of claim 3 , wherein both sense and antisense-strands of the siRNA contain dTdT on their 3′ terminus.
9. The chemically modified siRNA of claim 1 wherein a 3′ end of the sense strand terminates in a sequence UGdTdT-3′.
10. The chemically modified siRNA of claim 2 wherein a 3′ end of the sense strand terminates in a sequence UGdTdT-3′.
11. The chemically modified siRNA of claim 3 wherein a 3′ end of the sense strand terminates in a sequence UGdTdT-3′.
12. The chemically modified siRNA of claim 1 , wherein a length of either the sense or antisense strand is 21 nucleotides including the 3′ dTdT.
13. The chemically modified siRNA of claim 2 , wherein a length of either the sense or antisense strand is 21 nucleotides including the 3′ dTdT.
14. The chemically modified siRNA of claim 3 , wherein a length of either the sense or antisense strand is 21 nucleotides including the 3′ dTdT.
15. The chemically modified siRNA of claim 1 , wherein a total number of G+C of the sense strand are 9 nucleotides.
16. The chemically modified siRNA of claim 2 , wherein a total number of G+C of the sense strand are 9 nucleotides.
17. The chemically modified siRNA of claim 3 , wherein a total number of G+C of the sense strand are 9 nucleotides.
18. The chemically modified siRNA of claim 1 , wherein the 2′-OMe and PS2 modifications are in a backbone region adjacent to a 3′-dTdT overhang of the siRNA sense strand.
19. The chemically modified siRNA of claim 2 , wherein the 2′-OMe and PS2 modifications are in a backbone region adjacent to a 3′-dTdT overhang of the siRNA sense strand.
20. The chemically modified siRNA of claim 3 , wherein the 2′-OMe and PS2 modifications are in a backbone region adjacent to a 3′-dTdT overhang of the siRNA sense strand.